Increased B Cell and Cytotoxic NK Cell Proportions and Increased T Cell Responsiveness in Blood of Natalizumab-Treated Multiple Sclerosis Patients
Figure 4
Phenotypic characteristics of CD19+ B cell and CD3-CD56+ NK cell subpopulations in MS patients before and after one year of natalizumab treatment (pre and post, respectively).
p<0.01 is considered statistically significant. Comparisons are pairwise. Bars show mean values, whiskers denote SD.